- Home
- SSP vs PBYI Comparison
SSP vs PBYI Comparison
Compare SSP & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSP
- PBYI
- Stock Information
- Founded
- SSP 1878
- PBYI 2010
- Country
- SSP United States
- PBYI United States
- Employees
- SSP N/A
- PBYI N/A
- Industry
- SSP Broadcasting
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- SSP Industrials
- PBYI Health Care
- Exchange
- SSP Nasdaq
- PBYI Nasdaq
- Market Cap
- SSP 173.3M
- PBYI 176.1M
- IPO Year
- SSP 1988
- PBYI N/A
- Fundamental
- Price
- SSP $2.06
- PBYI $2.53
- Analyst Decision
- SSP Buy
- PBYI Strong Buy
- Analyst Count
- SSP 2
- PBYI 1
- Target Price
- SSP $7.75
- PBYI $7.00
- AVG Volume (30 Days)
- SSP 584.3K
- PBYI 330.8K
- Earning Date
- SSP 11-01-2024
- PBYI 10-31-2024
- Dividend Yield
- SSP N/A
- PBYI N/A
- EPS Growth
- SSP N/A
- PBYI N/A
- EPS
- SSP N/A
- PBYI 0.18
- Revenue
- SSP $2,317,391,000.00
- PBYI $219,143,000.00
- Revenue This Year
- SSP $8.99
- PBYI N/A
- Revenue Next Year
- SSP N/A
- PBYI N/A
- P/E Ratio
- SSP N/A
- PBYI $13.95
- Revenue Growth
- SSP N/A
- PBYI N/A
- 52 Week Low
- SSP $1.68
- PBYI $2.13
- 52 Week High
- SSP $9.35
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- SSP 49.36
- PBYI 44.27
- Support Level
- SSP $1.68
- PBYI $2.48
- Resistance Level
- SSP $2.15
- PBYI $2.64
- Average True Range (ATR)
- SSP 0.15
- PBYI 0.13
- MACD
- SSP 0.06
- PBYI 0.06
- Stochastic Oscillator
- SSP 88.30
- PBYI 73.17
About SSP E.W. Scripps Company (The)
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.